The new report explained that the link between psoriasis and sleep disorders “is likely multifactorial, driven by ...
Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how ...
Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and ...
Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and ...
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation. The Academy of Managed Care Pharmacy (AMCP) ...
Ultimate disposition showed 54% approval (7% same-day; 47% after multiple days) and 46% denial, with 27% rejected within 1 ...
Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...
The Greater Philadelphia Business Coalition on Health will anchor a NACDD-selected 2026 regional summit to expand employer ...
High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance ...
Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results